Cara Therapeutics Inc. (CARA) announced Friday morning that it has been granted a breakthrough therapy designation from the FDA for I.V. CR845 for the treatment of moderate-to-severe uremic pruritus in chronic kidney disease patients undergoing hemodialysis.
from RTT - Before the Bell http://ift.tt/2sSKMRp
via IFTTT
No comments:
Post a Comment